Earnings Insights · TransMedics (TMDX) · Q3 FY2026

TransMedics (TMDX) Q3 FY2026: TransMedics Q3 2026 Earnings: Revenue Growth Accelerates as Heart, Liver and Logistics Gain Share

By AlgovestIQ ResearchPublished

Share

Read TransMedics Group’s results announcement (Form 8-K, filed Nov 5, 2026)

Key earnings findings

TransMedics (TMDX) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed

  1. TransMedics reported Q3 FY2026 revenue of $203.0M against the $178.1M analyst estimate, a 14.0% beat, and EPS of $0.51 against the $0.30 analyst estimate.
  2. TransMedics raised full-year 2026 revenue guidance to $764M to $774M, including approximately $14M of revenue from PAD Aviation.
  3. TMDX closed at $88.24 on Nov 6, 2026, up 27.9% from $68.98 on Nov 5, 2026, the last close before the results were released.

Sources: TransMedics Group results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references

Did TransMedics beat earnings expectations?

Actual
Estimate
Surprise
Revenue
$203.0M
$178.1M
+14.0%
EPS
$0.51
$0.30
+71.4%
  • Revenue surprise across the last 8 reported quarters has ranged from -7.5% to 16.3%.

Reported figures against analyst estimates, compiled from AlgovestIQ data.

TransMedics reported third-quarter revenue of $203.0M, up 41% year over year, while GAAP diluted EPS declined to $0.46 from $0.66. The quarter showed continued strength in OCS adoption for liver and heart transplants and rapid growth in logistics services, including the initial contribution from PAD Aviation.

The investment story is increasingly centered on whether TransMedics can convert its expanding clinical pipeline, European logistics platform and kidney program into new revenue streams without further diluting margins or materially increasing capital needs.

Earnings Snapshot

MetricReportedChange
Total revenue$203.0MUp 41%
Organic revenue$193.6MUp 35%
Net product revenue$113.4MUp 29%
Service revenue$89.6MUp 60%
Organic service revenue$80.2MUp 43%
Gross margin58.5%Down 30 bps
Income from operations$28.1MUp 21%
Operating margin13.9%Down 230 bps
Adjusted operating income$28.9MUp 22%
Adjusted operating margin14.2%Down 220 bps
Net income$17.1MDown 30%
Diluted EPS$0.46Down 30%
Adjusted diluted EPS$0.51Down 24%
Cash$493.0MUp from $488.4M at year-end 2025

The Bigger Story

The quarter reinforced that TransMedics is gaining penetration in its existing liver and heart markets even as the overall U.S. deceased-donor volume declined 6% year over year, according to management. Liver and heart case volumes increased both sequentially and year over year despite typical third-quarter seasonality, helping organic revenue rise 35%.

The near-term financial benefit came primarily from the existing National OCS Program, or NOP, rather than from new clinical indications. Management said there was no meaningful revenue contribution yet from the ENHANCE Heart Part B or DENOVO Lung programs. Those programs, alongside the planned European NOP launch and OCS Kidney development, are instead the principal potential growth drivers for 2027 and beyond.

That distinction matters. TransMedics has demonstrated that it can grow its current business, but the next leg of the growth case depends on clinical execution, regulatory progress, reimbursement and commercialization in markets that are not yet contributing material revenue.

Revenue and Operating Performance

Revenue reached a quarterly record of $203.0M, including $113.4M of product revenue and $89.6M of service revenue. Product revenue increased 29%, driven by greater liver and heart case volumes. Service revenue rose 60%, reflecting higher NOP adoption, logistics revenue, pricing actions and the July 1 strategic investment in PAD Aviation.

PAD Aviation contributed $9.4M of charter-service revenue in the quarter. Excluding PAD, service revenue grew 43% and total organic revenue increased 35%. The distinction is important because the reported 41% revenue growth rate includes acquired aviation services without a prior-year comparison.

Management attributed the underlying growth to market-share gains across liver and heart, including donation after brain death and donation after circulatory death cases. It also cited deeper NOP adoption and engagement with organ procurement organizations, or OPOs, seeking to improve organ utilization.

U.S. transplant revenue was approximately $186M, up 34% year over year and 1% sequentially. By organ type, management said liver generated approximately $150M, heart approximately $33M and lung approximately $2M. International revenue was approximately $6.6M, up 82%, though it remains small relative to the U.S. business.

TransMedics’ internal logistics network remains an important operating differentiator. The company supported approximately 86% of NOP missions requiring air transport through its own fleet, above its stated steady-state goal of managing more than 80% internally. Management also noted that ground transportation represented a larger component of missions in the third quarter, meaning aviation-flight trends alone may not fully reflect case activity.

Profitability and Margins

Profitability grew in absolute dollars but declined as a percentage of revenue as TransMedics increased investment in clinical programs, product development, infrastructure and PAD Aviation.

Gross margin was 58.5%, compared with 58.8% a year earlier. The modest reported decline largely reflected a greater mix of lower-margin service revenue and the initial margin impact of PAD Aviation. Management said PAD diluted gross margin by 260 basis points; excluding PAD, gross margin was 61.1%, up approximately 230 basis points year over year.

Product gross margin improved 50 basis points to 79.2%, helped by lower scrap and improved inventory controls. Service gross margin rose 440 basis points to 32.2%, supported by pricing improvements, reduced use of supplemental aircraft lift, lower ground-transportation cost per mission and greater leverage of fixed operating costs.

Management expects some service-margin normalization in the fourth quarter, although it expects margins to remain above historical levels. That is a relevant caution after a particularly strong quarter in logistics efficiency.

Operating expenses rose 48% to $90.5M. Research, development and clinical-trial spending nearly doubled to $29.2M as TransMedics invested in OCS Kidney, next-generation OCS, ENHANCE Heart and DENOVO Lung. SG&A increased 33% to $61.3M, driven by headcount, NOP capacity, information technology, international expansion, the new headquarters and PAD Aviation.

As a result, operating margin declined to 13.9% from 16.2%. Adjusted operating margin was 14.2%, down from 16.4%. GAAP net income fell 30% to $17.1M, while adjusted net income declined 23% to $18.9M. Higher interest expense and a $7.0M income-tax provision also weighed on net income.

Interest expense increased to $7.3M from $3.5M in the prior-year quarter, including approximately $3.9M related to the finance lease for the new Somerville headquarters.

Demand, Customers and Pricing

Management’s central demand message was that TransMedics continued to take share despite a softer donor-volume backdrop. It cited stronger adoption of its liver and heart offerings, as well as positive physician feedback from the ENHANCE Heart Part A study, as contributors to broader use of the OCS platform.

The company completed enrollment of 175 patients in ENHANCE Heart Part A during September. While Part A addresses TransMedics’ existing heart indication and is not considered incremental revenue by management, the company said encouraging clinician experience with the enhanced system may have supported deeper adoption in the current market.

Pricing also aided service margins. Management said pricing adjustments helped offset higher fuel costs across service and logistics operations. It did not provide pricing details for CHOPS, the company’s controlled hypothermic organ preservation system, stating that commercial economics remain premature while the clinical programs and regulatory pathway advance.

In Europe, TransMedics won its first transplant-logistics tender in Italy’s Emilia-Romagna region through PAD Aviation. Management characterized the tender as multiyear and said it expects European growth to be built through regional tenders, established logistics budgets and reimbursement for OCS and NOP-type services. The company has not quantified the specific revenue contribution from the Italian award.

What is TransMedics’ guidance for FY 2026?

TransMedics raised full-year 2026 revenue guidance to $764M to $774M, including approximately $14M of revenue from PAD Aviation. The range implies growth of 26% to 28% compared with 2025.

Excluding PAD Aviation, the company expects revenue of $750M to $760M, representing growth of 24% to 26%. Its prior guidance excluding PAD was $737M to $757M.

Management maintained its full-year adjusted operating-margin outlook of 12.5% to 14.0%. The company said the range incorporates accelerated investment in OCS Kidney and other strategic programs.

The updated outlook assumes no meaningful fourth-quarter revenue from ENHANCE Heart Part B or DENOVO Lung. Management characterized the guidance as conservative given holiday-period uncertainty and noted that October flight activity was softer, although it said flight data are not a complete proxy for total transplant activity.

Strategic Pipeline and Outlook

The most consequential strategic developments occurred outside the income statement.

TransMedics received FDA approval for a continued-access protocol following completion of ENHANCE Heart Part A, allowing enrollment of an additional 90 patients. It also received IDE approvals for ENHANCE Heart Part B and DENOVO Lung, with CHOPS included as a control arm in both programs.

ENHANCE Heart Part B is designed to address donor hearts preserved within roughly four hours and is expected to enroll approximately 600 patients, including 400 using OCS and 200 using CHOPS. DENOVO Lung is expected to enroll approximately 450 patients, including 300 using OCS and 150 using CHOPS. Management expects both studies to become catalysts for its heart and lung businesses beginning in 2027, but that outcome depends on trial execution and eventual regulatory progress.

For OCS Kidney, management reiterated that first-in-human clinical experience is expected in the second half of 2027. It plans to discuss the kidney trial design in the first half of 2027. The kidney opportunity is potentially important because it would move TransMedics into the largest transplant market, but it remains a development-stage program rather than a near-term revenue contributor.

The company also expects to launch OCS NOP operations in Italy, the Netherlands and Belgium in the first half of 2027. Management sees transplant logistics as a commercial entry point in Europe, where it said logistics budgets and reimbursement infrastructure are already established.

Balance Sheet, Cash Flow and Capital

Cash totaled $493.0M at September 30, compared with $488.4M at December 31, 2025. Management said cash and cash equivalents increased by approximately $20M sequentially during the quarter.

The balance sheet also reflects the capital intensity of the expanding platform. Property, plant and equipment totaled $376.5M, while finance-lease right-of-use assets were $330.4M, primarily associated with the new headquarters. Finance-lease liabilities totaled $351.5M.

TransMedics also carried $455.0M of convertible senior notes, net, and $54.8M of current long-term debt. The company expects full-year interest expense of approximately $29M, including approximately $15.4M related to the headquarters finance lease, partially offset by roughly $11M of interest income.

The cash position provides flexibility for ongoing clinical and international investment, but the rising lease obligations, interest expense and development spending mean investors should continue to monitor cash generation as the company scales its logistics and product-development programs.

What Investors Should Watch

1. Organic growth after the PAD contribution

Organic revenue grew 35% in the third quarter, showing that growth was not solely acquisition-driven. Investors should watch whether product revenue can accelerate alongside service revenue as liver and heart adoption expands and newer clinical programs begin contributing.

2. Gross-margin durability

Reported gross margin fell slightly because service revenue represented a larger share of sales and PAD Aviation carried a lower margin profile. The company’s ability to retain logistics efficiencies and improve PAD’s economics will be central to sustaining margin expansion over time.

3. Fourth-quarter seasonality and guidance execution

Management acknowledged softer October flight activity but maintained that the final six to eight weeks of the fourth quarter have historically been stronger. Delivering the raised $764M to $774M full-year revenue range would support management’s view that the current business can overcome seasonal fluctuations.

4. ENHANCE, DENOVO and CHOPS milestones

The new heart and lung programs expand TransMedics’ potential markets, but their economic value remains unproven. Investors should watch enrollment progress, clinical results, regulatory timing and eventual commercialization plans for CHOPS.

5. European rollout and capital intensity

Italy’s first logistics tender establishes an initial commercial foothold, but European revenue will depend on winning additional tenders and successfully launching NOP operations. At the same time, the company must fund clinical development, aviation infrastructure and international expansion while maintaining profitability.

AlgovestIQ Takeaway

TransMedics delivered a strong top-line quarter. Revenue growth accelerated to 41%, organic growth remained robust at 35%, and the company grew liver and heart volumes despite a weaker U.S. donor-volume environment. Its logistics network also appears to be improving operationally, with service margins benefiting from pricing, greater internal transport capacity and lower costs per mission.

However, the earnings result was more mixed below revenue. Operating margin declined by 230 basis points and GAAP EPS fell 30%, reflecting substantial spending on clinical programs, infrastructure and expansion. PAD Aviation added revenue but lowered consolidated gross margin, making successful integration and margin improvement an important part of the financial case.

The central investment question is no longer simply whether TransMedics can expand its existing liver and heart business. The company has shown it can do that. The more important question is whether it can translate ENHANCE Heart, DENOVO Lung, CHOPS, European operations and OCS Kidney into incremental growth while preserving the economics of the platform.

Evidence that would strengthen the thesis includes continued organic growth above the company’s long-term revenue outlook, stable or improving service margins, successful trial enrollment and regulatory progress, and early evidence that European logistics contracts can support broader OCS adoption. Conversely, slowing core case growth, persistent margin dilution from PAD and service mix, delayed clinical milestones or a greater-than-expected rise in capital requirements would weaken the case for sustained operating leverage.

How did TMDX stock react?

TMDX closed at $88.24 on Nov 6, 2026, up 27.9% from $68.98 on Nov 5, 2026, the last close before the results were released.

SessionCloseChange
Nov 5, 2026 (before release)$68.98—
Nov 6, 2026$88.24+27.9%

Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.

More from this earnings season

References

  1. Management commentary, analyst questions and outlook discussed on the call. Source: TransMedics Group Q3 FY2026 earnings call transcript, as of Nov 5, 2026.
  2. Reported results, segment figures and guidance from the company's results announcement. Source: TransMedics Group Form 8-K, Item 2.02 (SEC EDGAR), as of Nov 5, 2026.
  3. Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Nov 5, 2026.

AI-generated analysis based on company-reported earnings data and earnings-call materials. Every reported figure is checked against TransMedics' earnings release and call transcript before publication. Not investment advice.